November 30, 2015 : Episode 1

Video

Conference Highlights, Three FDA Approvals, and More

Related Videos
Thierry Facon, MD
C. Ola Landgren, MD, PhD
Brian I. Rini, MD, FASCO
David Samuel Dicapua Siegel, MD
Marc Machaalani, MD
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Noa Biran, MD
Antonio Cigliola, MD
Brian I. Rini, MD, FASCO
Related Content
The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.
Published: July 25th 2024 | Updated: July 25th 2024

FDA Accepts Resubmission of BLA for Cosibelimab in Locally Advanced or Metastatic CSCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Image Credit: ©Dr_Microbe - stock.adobe.com
July 19th 2024

EMA Accepts MAA for Belantamab Mafodotin Combos in R/R Multiple Myeloma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Razane El Hajj Chehade, MD
July 18th 2024

Clear Cell Histology Associated With Increased Risk of irAEs in Metastatic RCC

C. Ola Landgren, MD, PhD, professor, medicine, chief, Division of Myeloma, Department of Medicine, director, Sylvester Myeloma Institute, co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
July 18th 2024

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment